A long non-coding RNA targets microRNA miR-34a to regulate colon cancer stem cell asymmetric division

  1. Lihua Wang
  2. Pengcheng Bu
  3. Yiwei Ai
  4. Tara Srinivasan
  5. Huanhuan Joyce Chen
  6. Kun Xiang
  7. Steven M Lipkin
  8. Xiling Shen  Is a corresponding author
  1. Cornell University, United States
  2. Duke University, United States
  3. Weill Corenll Medical College, United States
  4. Weill Cornell Medical College, United States

Abstract

The roles of long non-coding RNAs (lncRNAs) in regulating cancer and stem cells are being increasingly appreciated. Its diverse mechanisms provide the regulatory network with a bigger repertoire to increase complexity. Here we report a novel LncRNA, Lnc34a, that is enriched in colon cancer stem cells (CCSCs) and initiates asymmetric division by directly targeting the microRNA miR-34a to cause its spatial imbalance. Lnc34a recruits Dnmt3a via PHB2 and HDAC1 to methylate and deacetylate the miR-34a promoter simultaneously, hence epigenetically silencing miR-34a expression independent of its upstream regulator, p53. Lnc34a levels affect CCSC self-renewal and colorectal cancer (CRC) growth in xenograft models. Lnc34a is upregulated in late-stage CRCs, contributing to epigenetic miR-34a silencing and CRC proliferation. The fact that lncRNA targets microRNA highlights the regulatory complexity of non-coding RNAs (ncRNAs), which occupy the bulk of the genome.

Article and author information

Author details

  1. Lihua Wang

    Department of Biological and Environmental Engineering, Cornell University, Ithaca, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Pengcheng Bu

    Department of Biomedical Engineering, Duke University, Ithaca, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Yiwei Ai

    Department of Biomedical Engineering, Cornell University, Ithaca, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Tara Srinivasan

    Department of Biomedical Engineering, Cornell University, Ithaca, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Huanhuan Joyce Chen

    Meyer Cancer Center, Weill Corenll Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Kun Xiang

    Department of Biomedical Engineering, Cornell University, Ithaca, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Steven M Lipkin

    Deparments of Medicine, Genetic Medicine and Surgery, Weill Cornell Medical College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Xiling Shen

    Department of Biomedical Engineering, Duke University, Durham, United States
    For correspondence
    xs37@duke.edu
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Michael R Green, Howard Hughes Medical Institute, University of Massachusetts Medical School, United States

Ethics

Animal experimentation: All animal experiments were approved by The Cornell Center for Animal Resources and Education (CARE) and followed the protocol (2009-0071 and 2010-0100).

Human subjects: Frozen CRC specimens of different clinical stages were acquired from Weill Cornell Medical College (WCMC) Colon Cancer Biobank. The studies followed informed consent and approval of the IRB committee at Weill Cornell Medical College.

Version history

  1. Received: January 21, 2016
  2. Accepted: April 13, 2016
  3. Accepted Manuscript published: April 14, 2016 (version 1)
  4. Version of Record published: May 6, 2016 (version 2)

Copyright

© 2016, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,291
    Page views
  • 1,503
    Downloads
  • 109
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lihua Wang
  2. Pengcheng Bu
  3. Yiwei Ai
  4. Tara Srinivasan
  5. Huanhuan Joyce Chen
  6. Kun Xiang
  7. Steven M Lipkin
  8. Xiling Shen
(2016)
A long non-coding RNA targets microRNA miR-34a to regulate colon cancer stem cell asymmetric division
eLife 5:e14620.
https://doi.org/10.7554/eLife.14620

Share this article

https://doi.org/10.7554/eLife.14620

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Bingrui Li, Fernanda G Kugeratski, Raghu Kalluri
    Research Article

    Non-invasive early cancer diagnosis remains challenging due to the low sensitivity and specificity of current diagnostic approaches. Exosomes are membrane-bound nanovesicles secreted by all cells that contain DNA, RNA, and proteins that are representative of the parent cells. This property, along with the abundance of exosomes in biological fluids makes them compelling candidates as biomarkers. However, a rapid and flexible exosome-based diagnostic method to distinguish human cancers across cancer types in diverse biological fluids is yet to be defined. Here, we describe a novel machine learning-based computational method to distinguish cancers using a panel of proteins associated with exosomes. Employing datasets of exosome proteins from human cell lines, tissue, plasma, serum, and urine samples from a variety of cancers, we identify Clathrin Heavy Chain (CLTC), Ezrin, (EZR), Talin-1 (TLN1), Adenylyl cyclase-associated protein 1 (CAP1), and Moesin (MSN) as highly abundant universal biomarkers for exosomes and define three panels of pan-cancer exosome proteins that distinguish cancer exosomes from other exosomes and aid in classifying cancer subtypes employing random forest models. All the models using proteins from plasma, serum, or urine-derived exosomes yield AUROC scores higher than 0.91 and demonstrate superior performance compared to Support Vector Machine, K Nearest Neighbor Classifier and Gaussian Naive Bayes. This study provides a reliable protein biomarker signature associated with cancer exosomes with scalable machine learning capability for a sensitive and specific non-invasive method of cancer diagnosis.

    1. Cancer Biology
    Carolyn M Jablonowski, Waise Quarni ... Jun Yang
    Research Article

    Dysregulated pre-mRNA splicing and metabolism are two hallmarks of MYC-driven cancers. Pharmacological inhibition of both processes has been extensively investigated as potential therapeutic avenues in preclinical and clinical studies. However, how pre-mRNA splicing and metabolism are orchestrated in response to oncogenic stress and therapies is poorly understood. Here, we demonstrate that jumonji domain containing 6, arginine demethylase, and lysine hydroxylase, JMJD6, acts as a hub connecting splicing and metabolism in MYC-driven human neuroblastoma. JMJD6 cooperates with MYC in cellular transformation of murine neural crest cells by physically interacting with RNA binding proteins involved in pre-mRNA splicing and protein homeostasis. Notably, JMJD6 controls the alternative splicing of two isoforms of glutaminase (GLS), namely kidney-type glutaminase (KGA) and glutaminase C (GAC), which are rate-limiting enzymes of glutaminolysis in the central carbon metabolism in neuroblastoma. Further, we show that JMJD6 is correlated with the anti-cancer activity of indisulam, a ‘molecular glue’ that degrades splicing factor RBM39, which complexes with JMJD6. The indisulam-mediated cancer cell killing is at least partly dependent on the glutamine-related metabolic pathway mediated by JMJD6. Our findings reveal a cancer-promoting metabolic program is associated with alternative pre-mRNA splicing through JMJD6, providing a rationale to target JMJD6 as a therapeutic avenue for treating MYC-driven cancers.